BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 25201464)

  • 21. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.
    Tseng CH
    PLoS One; 2014; 9(10):e109852. PubMed ID: 25303400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus.
    Tseng CH
    Eur J Endocrinol; 2019 Jun; 180(6):365-372. PubMed ID: 30986765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin reduces risk of varicose veins in patients with type 2 diabetes.
    Tseng CH
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3206. PubMed ID: 31322821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.
    Tseng CH
    Eur J Clin Invest; 2016 Jan; 46(1):70-9. PubMed ID: 26584246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus.
    Tseng CH
    Metabolism; 2018 Aug; 85():223-226. PubMed ID: 29729227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
    Tseng CH
    Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes.
    Tseng CH
    J Am Acad Dermatol; 2018 Apr; 78(4):694-700. PubMed ID: 29246826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone is not associated with an increased risk of bladder cancer.
    Tseng CH
    Cancer Epidemiol; 2013 Aug; 37(4):385-9. PubMed ID: 23619142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan.
    Tseng CH
    Gynecol Oncol; 2013 Oct; 131(1):135-9. PubMed ID: 23877016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis.
    Tseng CH
    J Am Heart Assoc; 2019 Nov; 8(21):e011640. PubMed ID: 31630591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
    Tseng CH
    Oncotarget; 2016 Sep; 7(38):62687-62696. PubMed ID: 27409676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    Tseng CH
    BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
    Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
    Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.
    Tseng CH
    BMC Cancer; 2015 Feb; 15():41. PubMed ID: 25655946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680039
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of metformin in patients with prostate cancer and the risk of death.
    Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):2111-8. PubMed ID: 25017246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
    Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
    Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Kowall B; Stang A; Rathmann W; Kostev K
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    J Crohns Colitis; 2021 Jan; 15(1):64-73. PubMed ID: 32604412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.